Pembrolizumab plus axitinib showed superior overall survival and progression-free survival compared to sunitinib in advanced clear cell renal cell carcinoma. The combination therapy demonstrated a ...
"This announcement is an important step in increasing the awareness and accessibility of OnQ Prostate beyond its earliest adopters, so that more physicians and patients can benefit from this ...
Apalutamide shows a 23% reduction in mortality risk at 24 months compared to enzalutamide in mCSPC patients. The study's findings are consistent with the TITAN trial, confirming apalutamide's survival ...
David R. Wise, MD, PhD, discusses the potential for pasritamig combined with docetaxel to improve outcomes in patients with mCRPC. Wise is a genitourinary medical oncologist at NYU Langone Health and ...
Jonathan Rubenstein, MD, and Mark Painter answer a question regarding coding for use of the second-generation Calyxo CVAC system. Regarding your recent article, “Reporting use of ureter access sheath ...
The management of testicular cancer continues to evolve, with advances in diagnostics, risk stratification, and multimodal treatment shaping contemporary clinical practice. At the 41st Annual Congress ...
FIT-001 enrolled ccRCC patients with prior immunotherapy, KPS ≥70, and prior cabozantinib exposure, using darlifarnib 3/5/8 mg QD (7-on/7-off) plus cabozantinib 40/60 mg. Antitumor activity was ...
The FDA granted priority review to EV plus pembrolizumab as a perioperative regimen for cisplatin-eligible MIBC based on KEYNOTE-B15 data showing a 47% reduction in EFS events, a 35% reduction in the ...
VYBRIQUE is a sildenafil oral film formulated for discreet, water-free administration, aiming to reduce use barriers for patients for whom privacy and convenience influence ED treatment adherence. A ...
The Centers for Medicare & Medicaid Services (CMS) have established a payment rate for the ArteraAI prostate cancer test, a multimodal artificial intelligence (MMAI) biomarker test that can predict ...
Social media platforms are major sources of prostate cancer misinformation, affecting patient education and care provider relationships. Misinformation is often spread by unlicensed individuals posing ...
Dr. Shawn Zimberg and Dr. Dean Laganosky discuss the BioProtect Balloon Transplant System, a rectal spacer for use in prostate cancer radiation. Laganosky: The BioProtect rectal spacing device is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results